Clomid

Clomid

$120,00

Clomid is used on women who have anovulatory cycles (this refers to menstruation without ovulation) or irregular cycles to stimulate the ovary to produce eggs. Clomid is a registered trademark of Sanofi-Aventis.

Clomid (clomiphene) is a non-steroidal fertility medicine. It causes the pituitary gland to release hormones needed to stimulate ovulation (the release of an egg from the ovary). Clomid is used to cause ovulation in women with certain medical conditions (such as polycystic ovary syndrome) that prevent naturally occurring ovulation. Clomid may also be used for purposes not listed in this medication guide.

This medication is used to treat infertility in women. It works by stimulating an increase in the amount of hormones that support the growth and release of a mature egg (ovulation). This medication is not recommended for women whose ovaries no longer make eggs properly (primary pituitary or ovarian failure).

Clomid must be taken by mouth exactly as directed by your doctor in order to be most effective. It is important to follow your dosing schedule carefully. Your dosage is based on your medical condition and response to therapy. Do not take it more often or for a longer time than prescribed by your doctor. Long-term treatment with this medication is not recommended and should not be more than 6 cycles. You may be directed to record your body temperature, perform ovulation tests, and properly time sexual intercourse for best results. Ask your doctor if you have any questions.
Stop taking clomiphene and seek emergency medical attention if you experience an allergic reaction (difficulty breathing; closing of your throat; swelling of your lips, tongue, or face; or hives). The ovarian hyperstimulation syndrome (OHSS) has been reported to occur in patients receiving clomiphene. Symptoms of OHSS include swelling of the hands or legs, abdominal pain and swelling, shortness of breath, weight gain, and nausea or vomiting. OHSS can be fatal. Notify your doctor immediately or seek emergency medical attention if you develop any of these side effects. Other side effects may also occur. Notify your doctor if you experience ovarian enlargement presenting as abdominal or pelvic pain, tenderness, pressure, or swelling; flushing; nausea, vomiting, or diarrhea; breast tenderness or discomfort; blurred vision or other visual disturbances; headache; or abnormal uterine bleeding. Clomiphene may increase the likelihood of multiple births. Multiple births may carry additional risk both for the mother and for the fetuses. Side effects other than those listed here may also occur. Talk to your doctor about any side effect that seems unusual or that is especially bothersome.
Careful attention should be given to the selection of candidates for CLOMID therapy. Pelvic examination is necessary prior to CLOMID treatment and before each subsequent course. Pregnancy Fetal Risk Summary – Pregnancy Category X CLOMID use in pregnant women is contraindicated, as CLOMID treatment does not offer benefit in this population. Available human data do not suggest an increased risk for congenital anomalies above the background population risk. However, animal reproductive toxicology studies showed increased embryo-fetal loss and structural malformations in offspring. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential risks to the fetus. Clinical Considerations To avoid inadvertent CLOMID administration during early pregnancy, appropriate tests should be utilized during each treatment cycle to determine whether ovulation and/or pregnancy occurs. Patients should be evaluated carefully to exclude ovarian enlargement or ovarian cyst formation between each treatment cycle. The next course of CLOMID therapy should be delayed until these conditions have been excluded.
Drug interactions with CLOMID have not been documented. Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term toxicity studies in animals have not been performed to evaluate the carcinogenic or mutagenic potential of clomiphene citrate. Oral administration of CLOMID to male rats at doses of 0.3 or 1 mg/kg/day caused decreased fertility, while higher doses caused temporary infertility. Oral doses of 0.1 mg/kg/day in female rats temporarily interrupted the normal cyclic vaginal smear pattern and prevented conception. Doses of 0.3 mg/kg/day slightly reduced the number of ovulated ova and corpora lutea, while 3 mg/kg/day inhibited ovulation.